1Ametov AS, Barinov A, Dyck PJ, et al. The sensory symptoms of dia- betic polyneuropathy are improves with a-lipoic acid:the SYDNEY trial[ J]. Diabetes Care ,2003,25 ( 3 ) :770 - 776.
2Brownlee M. Biochemistry and molecular cell biology of diabetic complications [ J ]. Nature, 2001,414 ( 6865 ) : 813 - 820.
3Du X, Matsumura T, Edelstein D, et al. Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells [ J ]. J Clin Invest, 2003, 112(7) :1049 - 1057.
4Stevens M J, Obrosova I, Cao X, et al. Effects of DL-alpha-lipoie acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy [ J ]. Diabetes, 2000,49(6) :1006 - 1015.
5Androne L,Gavan NA,Veresiu IA,et al. In vivo effect of lipoic acidon lipid peroxidation in patients with diabetic neuropathy[ J]. In Vi- vo,2000,14(2) :327 -330.
6Hahm JR, Kim B J, Kim KW. Clinical experience with thioetaeid (thioctic aeid) in the treatment of distal symmetric polyneuropathy in Korean diabetic patients [ J ]. J Diabetes Complications, 2004,18 (2) :79 -85.
7Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic dia- betic polyneuropathy with the antioxidant oL-lipoie aeid:a meta anal- ysis [ J ]. Diabet Med,2004,21 ( 2 ) : 114 - 121.
8Hattori T, Matsubara A, Taniguehi K, et al. Aldose reduetase inhibi- tor fidarestat attenuates leukocyte-endothelial interactions in experi- mental diabetic rat retina in vivo[ J]. Curr Eye Res, 2010,35 (2) : 146 - 154.
9Nob HL, Hu Y, Park TS, et al. Regulation of plasma fructise and mortality in mice by the aldose reductase inhibitor lidorestat [ J ]. JPharrnacol Exp Ther,2009,328 ( 2 ) :496 - 503.
10Hotta N, Kawamori R, Atsumi Y, et al. Stratified analysis for selec- ting appropriate target patients with diabetic peripheral neuropathy for long'term treatment with an aldose reduetass inhibitor, epalrestat [ J ]. Diabet Med ,2008 ,25 ( 7 ) : 818 - 825.
